Nakuba ekuqaleni uCervarix ingase ingabonakali iyindlela enhle yokuvikela ukutheleleka nge- HPV ngocansi njengokungathi i- Gardasil noma i- Gardasil 9 , empeleni kuyisinqumo esihle sokugoma. Naphezu kokuba yenzelwe ukuvikela eminye imikhakha emibili ye- HPV engozini enkulu (16 no-18) evame ukuhlotshaniswa nomdlavuza womlomo wesibeletho (okungenani kubafazi baseCaucasus ), uma kuqhathaniswa neminye imithi ehlose ukuhlunga okungama-4 noma angu-9, Ucwaningo luhlinzeke ubufakazi obonisa ukuthi i-Cervarix empeleni inamandla okuhlinzeka ukuvikelwa emkhakheni we- oncogenic HPV, kuhlanganise, okungenzeka, i-HPV 31, 33, 35, 45, 52, no-58.
Kodwa-ke, ngokungafani ne-Garadsil, akunakwenzeka ukuvikela ngokumelene nanoma yiziphi izinkinga ezingezansi ezithinta ama- warts omzimba .
I-Cervarix ayinayo yedwa amandla ayo okuhlinzeka ngokuvikeleka okuphambene nezinye izinhlobo ze-HPV. I-Gardasil ibonakala nokuba nekhono elithile lokunikeza ukuvikelwa okuphambene nezinhlobo ezihlukahlukene ze-HPV, kodwa ubufakazi obusesikhathini, nakuba kungavumelani, bubonisa ukuthi izinga lokuvikelwa okungahambi kahle lingahle libe likhulu njengoCervarix. Ngaphezu kwalokho, abanye abacwaningi abaqhathanisa ikhono lemijovo emibili yokuvikela eminye imikhakha ye-HPV bathole ubufakazi obukhomba ukuthi ukuvikelwa yiCervarix kungadlulela isikhathi eside kunokuba kuvikelwe iGadasil.
Ngamafuphi, inani eliphelele lobufakazi liphakamisa ukuthi inkinga yokugoma i-HPV ingumuntu omuhle ... nokuthi imithi emibili ingase ibe yindleko efana nayo. Inzuzo enkulu ye-Gardasil yikhono layo lokuvikela emilenzeni yezocansi kanye nezinhlobo ezahlukene zomdlavuza .
Inzuzo enkulu yeCervarix yukuthi ingase inikeze isivikelo esinamandla nakakhulu ngokuhlukana kwezifo zomdlavuza.
Oh, futhi kukhona enye inzuzo engaba khona yeCervarix ngaphezu kweGarasil, okungenani ngesibalo esincane sabantu. Ngasekupheleni kuka-2013, i-European Commission ivume isimiso sokunciphisa isimo sokunciphisa imijovo emibili, esikhundleni sezintathu, ngamantombazane aneminyaka engu-9 kuya ku-14.
Isimiso se-2-dose asikavunyelwe e-United States, kodwa uma futhi nini, lokho kungaba isisusa esinamandla kwabanye abantu ukuthi bakhethe ukugoma noCervarix ngaphezu kokugoma noma i-Gardasil shot. Uma ungumuntu ozonda ama-injection, noma uma unezimali noma ezinye izinto ezikhathazayo mayelana nokugoma, ukuqedwa ngemuva kokudubula okubili kungase kukhange kakhulu kunokudinga ukubuya inombolo yesithathu yokudubula.
Imithombo:
I-Bissett SL, i-Draper E, i-Myers RE, i-Godi A, i-Beddows S. I-anti-neutralizing antibodies esetshenziswe yi-Cervarix® yomuntu wokugoma i-papillomavirus ibonisa izinhlobo ezahlukene ze-Alpha-9. Umgomo. 2014 Feb 26; 32 (10): 1139-46. i-doi: 10.1016 / j.vaccine.2014.01.008.
Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, MP MP, Lin L, Struyf F, Dubin G. Ukuqhathaniswa kwe-immunogenicity yesikhathi eside nokuphepha komuntu we-papillomavirus (HPV) -16 / 18 Umgomo wokugoma we-AS04 nomgomo we-HPV-6/11/16/18 kubesifazane abanempilo abaneminyaka engama-18-45: Ukuhlaziywa kokuphela kokuhlolwa kwesicwaningo se-Phase III esihleliwe. I-Hum Vaccin Immunother. 2014; 10 (12): 3435-45. i-doi: 10.4161 / hv.36121.
U-Kohli M, u-Lawrence D, u-Haig J, u-Anonychuk A, u-Demarteau N. Ukulinganisa umthelela wokwahlukana kwedatha yokuvikelwa kokuphambana phakathi kwepillomavirus yomuntu (HPV) -16/18 umuthi wokugoma we-AS04 kanye ne-papillomavirus yomuntu (HPV) -6 / 11/16/18 ukugonywa eCanada. I-BMC Impilo Yomphakathi. 2012 Okthoba 13; 12: 872. i-doi: 10.1186 / 1471-2458-12-872.
UMalagón T, i-drolet M, i-Boily MC, i-Franco EL, i-Jit M, i-Brisson J, i-Brisson M. i-Cross-protective ukusebenza kwamagciwane amabili omzimba we-papillomavirus: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. I-Lancet I-Dis Infect. 2012 Oct; 12 (10): 781-9.
UNakalembe M, uBanura C, uNamujju PB, uMirembe FM. Amazinga we-anti-HPV16 / 18 ne-anti-HPV31 / 33/35/45/52/58 antibodies phakathi kwama-AS04-adjuvanted HPV16 / 18 agonywe futhi angagonywanga amantombazane ase-Uganda eneminyaka engu-10-16. I-Cancer Engaguquki Yama-Agent. 2014 Sep 1; 9: 29. i-doi: 10.1186 / 1750-9378-9-29.
Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS. Ukuqhathaniswa kwe-immunogenicity ye-Cervarix® ne-Gardasil® yemithi ye-papillomavirus yabantu ye-oncogenic non-vaccine serotypes HPV-31, HPV-33, ne-HPV-45 kubantu abadala abanegciwane lesandulela ngculaza. I-Hum Vaccin Immunother. 2014 Meyi; 10 (5): 1147-54. i-doi: 10.4161 / hv.27925.